Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial
Autore:
Gullestad, L; Manhenke, C; Aarsland, T; Skardal, R; Fagertun, H; Wikstrand, J; Kjekshus, J;
Indirizzi:
Natl Hosp Norway, Dept Cardiol, Div Heart & Lung Dis, N-0027 Oslo, Norway Natl Hosp Norway Oslo Norway N-0027 eart & Lung Dis, N-0027 Oslo, Norway Hjertelaget Res Fdn, Stavanger, Norway Hjertelaget Res Fdn Stavanger Norway telaget Res Fdn, Stavanger, Norway Scandinavian Stat Serv, Oslo, Norway Scandinavian Stat Serv Oslo NorwayScandinavian Stat Serv, Oslo, Norway Univ Gothenburg, Wallenberg Lab Cardiovasc Res, Gothenburg, Sweden Univ Gothenburg Gothenburg Sweden ab Cardiovasc Res, Gothenburg, Sweden
Titolo Testata:
EUROPEAN JOURNAL OF HEART FAILURE
fascicolo: 4, volume: 3, anno: 2001,
pagine: 463 - 468
SICI:
1388-9842(200108)3:4<463:EOMCOE>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
IDIOPATHIC DILATED CARDIOMYOPATHY; BETA-ADRENERGIC-BLOCKADE; DOUBLE-BLIND; VASODILATOR THERAPY; RANDOMIZED TRIAL; FAILING HEART; CARVEDILOL; SYMPTOMS; TERM; MORTALITY;
Keywords:
beta-blockade; exercise; oxygen uptake;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Gullestad, L Baerum Hosp, Dept Med, N-1306 Baerum Postterminal, Norway Baerum Hosp Baerum Postterminal Norway N-1306 minal, Norway
Citazione:
L. Gullestad et al., "Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial", EUR J HE FA, 3(4), 2001, pp. 463-468

Abstract

Background: beta -Blockade usually causes a slight reduction in exercise capacity among healthy subjects, while more variable results have been observed in chronic heart failure (CHF), probably related to patients studied, methods and agent used. The effect of metoprolol controlled release/extendedrelease (CR/XL) on peak oxygen uptake (peak VO2) in this patient population has not previously been investigated. Aims: We examined the effect of long-term treatment with the selective beta (1)-receptor blocker metoprolol CR/XL once daily on exercise capacity in patients with CHF. Methods: Ninety-four patients (70 males and 24 females; mean age 63.6 +/- 10.6 years) with chronic symptomatic heart failure in New York Heart Association (NYHA) functional class II-IV, and with ejection fraction less than or equal to 40%, stabilized on optimum standard therapy were randomized to metoprolol CR/XL orplacebo in a double-blind trial. Exercise capacity was evaluated by peak VO2 at baseline, after 3 months and at the end of study (mean follow-up 11.4+/- 0.4 months). Results: Compared with placebo metoprolol CR/XL produced a significant decrease in heart rate by 11 beats/min at rest and 18 beats/min at peak exercise. There was a tendency for a temporal decline in peak VO2 after 3 months of therapy in both groups, but altogether peak VO2 remained unchanged from baseline with no difference between the groups at I year. Conclusions: In patients with moderate to severe CHF, 11.4 months of beta (1)-blockade with metoprolol CR/XL had no effect on exercise capacity when compared with placebo or baseline. (C) 2001 European Society of Cardiology. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 06:33:36